Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center
Introduction Palbociclib, the first CDK4/6 inhibitor, has shown promising results in phase III clinical studies by enhancing the efficacy of endocrine therapy (ET) in HR +/HER2– advanced breast cancer. However, real-world data on its use in patients with visceral metastatic disease are li...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2025-04-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1790584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|